TY - JOUR AU - Lara, Pedro C AU - Rodriguez-Melcon, Juan I AU - Palacios-Eito, Amalia AU - Lozano, Antonio AU - Hervas-Moron, Asuncion AU - Villafranca, Elena AU - Gomez-Iturriaga, Alfonso AU - Sancho, Gemma AU - Maldonado, Xavier PY - 2022 DO - 10.3389/fonc.2022.891886 SN - 2234-943X UR - http://hdl.handle.net/10668/20683 T2 - Frontiers in oncology AB - Intermediate-risk prostate cancer (PCa) is usually treated by a combination of external beam radiation therapy (EBRT) and a short course of androgen deprivation therapy (ADT). ADT is associated with multiple side effects, including weight gain, loss... LA - en PB - Frontiers Research Foundation KW - Enzalutamide monotherapy KW - Hypofractionated KW - Intermediate risk KW - Prostate cancer KW - Radiotherapy TI - Phase II Study of ENZAlutamide Combined With Hypofractionated Radiation Therapy (ENZART) for Localized Intermediate Risk Prostate Cancer. TY - research article VL - 12 ER -